Articles related to FDA

Discover how Elrexfio’s conditional FDA approval could redefine the treatment landscape for patients with difficult-to-treat multiple myeloma. Dive into the promising clinical trial results and understand its potential impact on your practice.

Discover how AOC 1044’s recent FDA orphan drug designation could revolutionize the treatment landscape for Duchenne muscular dystrophy patients with exon 44 mutations. Stay tuned for upcoming results from the EXPLORE44 trial.

The FDA’s recent decision allows Fulcrum Therapeutics to continue its Phase 1b trial of FTX-6058, an oral therapy for SCD. The trial aims to explore the drug’s potential in increasing fetal hemoglobin levels, offering a new avenue for treatment.

Xdemvy, backed by robust clinical trials, offers a new, targeted treatment option for Demodex blepharitis. The FDA-approved solution is expected to be available by the end of August 2023.

GE HealthCare’s Portrait Mobile, recently cleared by the FDA, offers a novel approach to patient monitoring, allowing continuous oversight without confining patients to their beds. Explore how this innovative technology could redefine hospital care practices.

The recent FDA approval of brexpiprazole for Alzheimer’s dementia patients has ignited concerns among healthcare professionals. Physicians are urged to carefully consider the drug’s minimal efficacy and increased mortality risk in their treatment decisions.